{"nctId":"NCT01958476","briefTitle":"Improving Outcomes in Neonatal Abstinence Syndrome","startDateStruct":{"date":"2013-09"},"conditions":["Neonatal Abstinence Syndrome","Neonatal Opioid Withdrawal"],"count":117,"armGroups":[{"label":"Neonatal Morphine Solution","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Neonatal Morphine Solution","Drug: Phenobarbital"]},{"label":"Methadone","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Methadone","Drug: Phenobarbital"]}],"interventions":[{"name":"Neonatal Morphine Solution","otherNames":["Morphine sulfate"]},{"name":"Methadone","otherNames":["Methadone oral solution"]},{"name":"Phenobarbital","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion criteria:\n\n1. Mother receiving methadone or buprenorphine (BPH) from a licensed physician or drug treatment program, or an opioid prescribed by a licensed health care worker for treatment of chronic pain.\n2. Need for treatment of NAS by Finnegan Scoring criteria\n3. Gestational age \\>37 weeks at birth defined by best obstetrical estimate\n4. Medically stable in the opinion of the Attending Physician\n5. Mother receiving \"adequate\" or \"intermediate\" prenatal care from a qualified physician or midwife as defined by the Prenatal Care Adequacy Index\n6. Singleton pregnancy\n7. Mother able to provide informed consent\n8. Infant able to take oral medications\n\nExclusion criteria:\n\n1. Gestation \\<37 weeks at entry defined by best obstetrical estimate\n2. Major congenital abnormalities including genetic syndromes\n3. Serious medical illness such as sepsis, asphyxia, seizures, or respiratory failure\n4. Mother abusing alcohol during pregnancy (average of 3 or more drinks per week in the last 30 days)\n5. Multiple gestations\n6. Mother received \"inadequate\" prenatal care as defined by the Prenatal Care Adequacy Index.","healthyVolunteers":false,"sex":"ALL","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Length of Hospital Stay (LOS)","description":"Participants were monitored for the duration of their hospitalization, an expected mean of 22 days.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"21.8","spread":"15"},{"groupId":"OG001","value":"23.2","spread":"8.8"}]}]}]},{"type":"SECONDARY","title":"Length of Hospital Stay (LOS) Due to Neonatal Abstinence Syndrome (NAS)","description":"Participants were monitored for the duration of their hospitalization attributable to NAS only.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"18.9","spread":"7.9"},{"groupId":"OG001","value":"21.1","spread":"6.9"}]}]}]},{"type":"SECONDARY","title":"Length of Treatment (LOT)","description":"Total number of days infant treated with replacement opioids while admitted to the hospital.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14.7","spread":"8.0"},{"groupId":"OG001","value":"16.6","spread":"6.9"}]}]}]},{"type":"SECONDARY","title":"Maximum Daily Dose of Replacement Opioid","description":"Maximum daily dose of neonatal morphine solution or methadone during the hospitalization","classes":[]},{"type":"SECONDARY","title":"Mean Finnegan Score (FS)","description":"Mean Finnegan withdrawal score during the duration of hospitalization.","classes":[]},{"type":"SECONDARY","title":"Number of Infants Needing a Second NAS Medication","description":"Number of infants treated with a second medication following protocol, phenobarbital. If the Finnegan Score remained elevated (still scored ≥8 two times consecutively, or still scored once ≥12) despite increasing to a predetermined maximal opioid dose (methadone or morphine), phenobarbital was administered (20-mg/kg loading dose followed by 4-5 mg/kg daily).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"17","spread":null}]}]}]},{"type":"SECONDARY","title":"Growth Outcome: Weight Change From Birth to 18 Months","description":"Growth outcome weight (lbs) depicted as difference in averaged weights from birth to 18 month follow-up visit. Standard deviations were averaged between birth and 18 mo time points.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19.1","spread":"2.5"},{"groupId":"OG001","value":"18.7","spread":"2.8"}]}]}]},{"type":"SECONDARY","title":"Growth Outcome: Head Circumference at 18 Months","description":"Average head circumference growth outcome at 18 month follow-up visit.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"47.8","spread":"2.4"},{"groupId":"OG001","value":"48.2","spread":"2.3"}]}]}]},{"type":"SECONDARY","title":"Maximum Finnegan Score","description":"Maximum Finnegan score during the hospitalization","classes":[]},{"type":"SECONDARY","title":"Growth Outcome: Length at 18 Months","description":"Average length (cm) at 18 month follow-up visit.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"82.1","spread":"4.6"},{"groupId":"OG001","value":"81.7","spread":"5.2"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Cognitive, Language, and Motor Development From 18 Month Bayley III Neurodevelopmental Assessment","description":"The Bayley Scales of Infant and Toddler Development (BSID-III) assesses the development of infants and children (1-42 months) through a series of developmental play tasks, identifying children with developmental delay. Raw scores of completed items are summarized within three distinct scale scores (Cognitive Scale, Language Scale, Motor Scale). Scale scores are each converted to composite scores to determine the child's performance compared with scores of age-matched children of typical development (percentile rank). A higher composite score indicates more ideal developmental outcome (range 40-160). At 18 month follow-up visit, participants were assessed using the BSID-III for cognitive, language and motor scale composite score outcomes.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100.1","spread":"21.6"},{"groupId":"OG001","value":"98.1","spread":"17.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"96.0","spread":"17.1"},{"groupId":"OG001","value":"94.2","spread":"18.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"103.6","spread":"17.3"},{"groupId":"OG001","value":"99.1","spread":"17.2"}]}]}]},{"type":"POST_HOC","title":"Number of Infants Needing a Dose Increase","description":"One Finnegan score ≥12, or two consecutive scores ≥8 affirms the requirement for pharmacological treatment or increasing treatment dosage. If the infant continued to have two consecutive Finnegan Scores ≥8 two times consecutively, or one ≥12, the dose was increased to the next level. (Level I: 0.3 mg/kg/day) (Level II: 0.5 mg/kg/day) (Level III: 0.7 mg/kg/day)\n\nA higher Finnegan score indicates greater severity of NAS (min 0, max 50).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22","spread":null},{"groupId":"OG001","value":"28","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":5,"n":58},"commonTop":["Excessive sleepiness/somnolence","Bradychardia","Hypothermia","Stridor/desaturation/shalllow breathing","Apnea and shallow breathing episodes"]}}}